title: Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients.
abstract: BACKGROUND
  Previous studies in rats indicated that thiazide-type diuretics reduced blood pressure (BP) and triggered baroreflex-mediated increase in sympathetic nerve activity (SNA), whereas spironolactone exerted central sympathoinhibitory action in addition to diuretic effects.
  
  
  OBJECTIVE
  The objectives were to determine effects of spironolactone and chlorthalidone on SNA and the role of SNA on diuretic-induced insulin resistance in human hypertension.
  
  
  METHODS
  We conducted a randomized crossover study in 23 untreated hypertensive patients in which we measured muscle SNA at baseline, after 1 and 3 months of chlorthalidone (12.5-25 mg/d), and after 1 and 3 months of spironolactone (50-75 mg/d). Ambulatory BP, baroreflex sensitivity, and indices of insulin resistance were also assessed at baseline and after 3 months of each drug treatment.
  
  
  RESULTS
  Chlorthalidone caused a similar reduction in ambulatory BP from baseline when compared with spironolactone (11 +/- 2/4 +/- 2 and 10 +/- 2/4 +/- 2 mm Hg, respectively). However, chlorthalidone increased SNA by 23% (P < 0.01) within 1 month of treatment, whereas spironolactone had no effect in the same subjects. SNA continued to be elevated after 3 months of chlorthalidone when compared with baseline and spironolactone. Baroreflex control of SNA was unaffected by either drug. Chlorthalidone increased indices of insulin resistance, which were significantly correlated with increases in SNA from baseline, whereas spironolactone had no effect in the same subjects.
  
  
  CONCLUSIONS
  Our data suggest that chlorthalidone, the first-line drug therapy for hypertension, causes persistent activation of sympathetic nervous system and insulin resistance in hypertensive patients. These side effects, however, are avoided by spironolactone despite similar reduction in BP.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8586, USA.
authors.forename: Dileep V
authors.initials: DV
authors.lastname: Menon
authors.forename: Debbie
authors.initials: D
authors.lastname: Arbique
authors.forename: Zhongyun
authors.initials: Z
authors.lastname: Wang
authors.forename: Beverley
authors.initials: B
authors.lastname: Adams-Huet
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Auchus
authors.forename: Wanpen
authors.initials: W
authors.lastname: Vongpatanasin
mesh_terms: D000450:Aldosterone / Q000097:blood; D000704:Analysis of Variance; D001794:Blood Pressure / Q000187:drug effects; D002752:Chlorthalidone / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004232:Diuretics / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D018482:Muscle, Skeletal / Q000294:innervation*; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use*; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D004232:Diuretics; D007328:Insulin; D013148:Spironolactone; D000450:Aldosterone; D012083:Renin; D002752:Chlorthalidone; D011188:Potassium